We are live on ! Find out more

Kamada

KMDA

Market cap $444M

7.70 USD

-0.25

3.14%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

7.65

-0.05

0.65%

1 day

-3.14%

5 days

-1.41%

1 month

-8.98%

3 months

8.45%

6 months

-5.41%

Year to date

9.53%

1 year

12.9%

5 years

30.73%

10 years

33.91%

About: Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Employees: 462

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35%

Neutral 65%

Negative 0%

Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026

REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030 Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

Kamada NASDAQ: KMDA outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand through product sales, distribution agreements, plasma supply and potential acquisitions.

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million Annually Kamada's Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel.

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company's ordinary shares (totaling approximately $9.8 million) announced on August 17, 2026 (the “Dividend”), expected to be paid on September 17, 2026 (the “Payment Date”), to shareholders of record at the close of business on August 27, 2026 (the “Record Date”).

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The Cure

For investors seeking opportunities outside the AI trade, healthcare stocks can offer diversification without sacrificing exposure to growth. S&P 500 healthcare earnings are projected to rise by 22% YoY in 2027, the second-highest estimated growth rate among the eleven sectors, topped only by technology. According to JPMorgan analysts, at a time when many investors remain highly concentrated in the AI theme, healthcare offers a rare combo of durable growth, tech-like margins, and value.

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The Cure

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

Zacks Investment Research

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks Investment Research

KMDA or PRTA: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?

KMDA or PRTA: Which Is the Better Value Stock Right Now?

See News Rankings

Price charts implemented using Lightweight Charts™